Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 5
Submit an article Journal homepage
209
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Arsenic trioxide and all-trans retinoic acid in the treatment of children with newly diagnosed acute promyelocytic leukemia

Shuang-Yue Lia Department of Hematology, Yinzhou Hospital Affiliated to Medical School of Ningbo University, Ningbo, ChinaORCID Iconhttps://orcid.org/0000-0003-2897-4205
ORCID Icon,
Ying Lua Department of Hematology, Yinzhou Hospital Affiliated to Medical School of Ningbo University, Ningbo, China
,
Hsiao-Chuan Liub Department of Radiology, Mayo Clinic, Rochester, NY, USAORCID Iconhttps://orcid.org/0000-0002-5410-8821
ORCID Icon,
Eun Ji Gangc Department of Pediatrics, Division of Hematology and Oncology, Children’s Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA, USAORCID Iconhttps://orcid.org/0000-0002-7475-2059
ORCID Icon,
Jing Led Department of Hematology, Ningbo Medical Centre Lihuili Hospital, Ningbo, China
,
Su-Ying Qiane Department of Hematology, Hwa Mei hospital, University of Chinese Academy of Science (Ningbo No. 2 Hospital), Ningbo, China
,
Shan-Hao Tanga Department of Hematology, Yinzhou Hospital Affiliated to Medical School of Ningbo University, Ningbo, China
,
Ting Sia Department of Hematology, Yinzhou Hospital Affiliated to Medical School of Ningbo University, Ningbo, China
&
Ren-Zhi Peia Department of Hematology, Yinzhou Hospital Affiliated to Medical School of Ningbo University, Ningbo, ChinaCorrespondence[email protected]
 show all
Pages 1267-1270 | Received 21 Apr 2020, Accepted 20 Nov 2020, Published online: 13 Jan 2021

References

  • Testi AM, D’Angiò M, Locatelli F, et al. Acute promyelocytic leukemia (APL): comparison between children and adults. Mediterr J Hematol Infect Dis. 2014;6(1):e2014032.
  • Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89(9):3354–3360.
  • Zhou J, Zhang Y, Li J, et al. Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia. Blood. 2010;115(9):1697–1702.
  • George B, Mathews V, Poonkuzhali B, et al. Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experience. Leukemia. 2004;18(10):1587–1590.
  • Burnett AK, Russell NH, Hills RK, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16(13):1295–1305.
  • Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369(2):111–121.
  • Abaza Y, Kantarjian H, Garcia-Manero G, et al. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017;129(10):1275–1283.
  • Platzbecker U, Avvisati G, Cicconi L, et al. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. J Clin Oncol. 2017;35(6):605–612.
  • Kutny MA, Alonzo TA, Gerbing RB, et al. Arsenic trioxide consolidation allows anthracycline dose reduction for pediatric patients with acute promyelocytic leukemia: report from the children’s oncology group phase III historically controlled trial AAML0631. J Clin Oncol. 2017;35(26):3021–3029.
  • Kutny MA, Geyer S, Laumann KM, et al. Outcome for pediatric acute promyelocytic leukemia patients at Children’s Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance). Pediatr Blood Cancer. 2019;66(3):e27542.
  • Yang MH, Wan WQ, Luo JS, et al. Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: interim results of the SCCLG-APL clinical study. Am J Hematol. 2018;93(12):1467–1473.
  • Testi AM, Biondi A, Lo Coco F, et al. GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood. 2005;106(2):447–453.
  • Creutzig U, Dworzak MN, Bochennek K, et al. First experience of the AML-Berlin-Frankfurt-Munster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid. Pediatr Blood Cancer. 2017; 64(8):e26461.
  • Testi AM, Pession A, Diverio D, et al. Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL. Blood. 2018;132(4):405–412.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.